Stock A068270 CELLTRION, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
176,600 KRW -0.45% Intraday chart for Celltrion, Inc. +2.14% -12.36%
Apr. 24 Market Share of Celltrion’s Remsima Rises to 74% in Europe MT
Apr. 17 Celltrion, Inc. announces an Equity Buyback for 436,047 shares. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 24,175,552 48,989,351 27,592,583 23,000,359 27,970,378 36,605,023 - -
Enterprise Value (EV) 2 24,047 49,090 27,117 23,236 27,970 37,261 36,902 36,077
P/E ratio 77.7 x 94.4 x 47.2 x 41.6 x - 70.7 x 32.9 x 25.6 x
Yield - - 0.38% - - 0.24% 0.25% 0.26%
Capitalization / Revenue 21.4 x 26.5 x 14.6 x 10.1 x 12.9 x 10.7 x 8.77 x 7.27 x
EV / Revenue 21.3 x 26.5 x 14.3 x 10.2 x 12.9 x 10.9 x 8.85 x 7.17 x
EV / EBITDA 44.8 x 55.1 x 27.9 x 26.6 x - 42.2 x 22.9 x 18.9 x
EV / FCF 63.3 x 186 x 46 x -211 x - 73.5 x 39.3 x 30 x
FCF Yield 1.58% 0.54% 2.17% -0.47% - 1.36% 2.55% 3.34%
Price to Book 8.27 x 14.4 x 6.87 x 5.34 x - 2.21 x 2.6 x 2.03 x
Nbr of stocks (in thousands) 144,521 144,757 144,931 143,304 138,811 207,276 - -
Reference price 3 167,280 338,424 190,385 160,500 201,500 176,600 176,600 176,600
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,128 1,849 1,891 2,284 2,176 3,428 4,172 5,035
EBITDA 1 537.3 891.4 972.1 873.6 - 883.4 1,609 1,910
EBIT 1 378.1 712.1 753.9 647.2 651.5 649.4 1,511 2,193
Operating Margin 33.5% 38.51% 39.87% 28.34% 29.93% 18.95% 36.23% 43.57%
Earnings before Tax (EBT) 1 378.6 650.7 746.9 626.2 671.1 638 1,507 2,227
Net income 1 297.6 511.3 575.1 533.2 535.6 504.5 1,099 1,720
Net margin 26.37% 27.65% 30.42% 23.34% 24.61% 14.72% 26.35% 34.17%
EPS 2 2,153 3,586 4,031 3,855 - 2,497 5,373 6,902
Free Cash Flow 3 379,716 263,739 589,594 -110,305 - 507,000 939,333 1,204,000
FCF margin 33,649.04% 14,262.95% 31,181.9% -4,829.54% - 14,791.8% 22,515.43% 23,913.97%
FCF Conversion (EBITDA) 70,673.9% 29,586.45% 60,648.72% - - 57,394.68% 58,373.2% 63,029.17%
FCF Conversion (Net income) 127,593.57% 51,582.76% 102,521.45% - - 100,495.54% 85,449.43% 69,986.44%
Dividend per Share 2 - - 721.2 - - 415.9 437.2 467.4
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 401 601.1 550.6 596.1 645.6 510.6 597.5 524 672.3 382.6 723.5 774.6 930.4 1,046 969.4
EBITDA 1 - - - - - - - - - - 131 200 265 350 445
EBIT 1 164 219 142.3 199 213.8 100.6 182.4 183 267.6 18.42 7.683 53.13 241.7 341.7 320.8
Operating Margin 40.9% 36.43% 25.84% 33.38% 33.11% 19.71% 30.52% 34.92% 39.81% 4.82% 1.06% 6.86% 25.98% 32.68% 33.09%
Earnings before Tax (EBT) 187.6 145.2 - 226.8 217.3 48.49 208.2 189.7 282.9 - - - - - -
Net income 1 135.5 120.5 118.5 183.4 166.7 64.53 166.9 147.5 221.8 1.054 8 49.25 201.2 268 296
Net margin 33.79% 20.04% 21.53% 30.77% 25.82% 12.64% 27.93% 28.15% 33% 0.28% 1.11% 6.36% 21.63% 25.63% 30.53%
EPS - - - - 1,162 470.0 1,155 1,034 1,561 - - - - - -
Dividend per Share 2 - - - - - - - - - - - - - 200.0 -
Announcement Date 11/10/21 2/16/22 5/12/22 8/5/22 11/9/22 3/3/23 5/8/23 8/14/23 11/7/23 2/29/24 - - - - -
1KRW in Billions2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 100 - 236 - 656 297 -
Net Cash position 1 128 - 476 - - - - 528
Leverage (Debt/EBITDA) - 0.1126 x - 0.2696 x - 0.7423 x 0.1845 x -
Free Cash Flow 2 379,716 263,739 589,594 -110,305 - 507,000 939,333 1,204,000
ROE (net income / shareholders' equity) 11.2% 16.7% 16.5% 12.9% - 3.99% 8.2% 7.84%
ROA (Net income/ Total Assets) 8.02% 11.6% 10.7% 9.22% - 2.73% 5.35% 7.45%
Assets 1 3,713 4,402 5,372 5,783 - 18,514 20,547 23,092
Book Value Per Share 3 20,218 23,501 27,732 30,040 - 79,867 68,008 87,032
Cash Flow per Share 3 3,430 2,460 6,417 6.250 - 3,959 7,788 10,103
Capex 1 94.3 87 63.4 111 - 88.3 91 90
Capex / Sales 8.35% 4.71% 3.35% 4.87% - 2.57% 2.18% 1.79%
Announcement Date 2/19/20 2/22/21 2/16/22 3/3/23 2/29/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Celltrion, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
176,600 KRW
Average target price
227,765 KRW
Spread / Average Target
+28.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-16.98% 10.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A068270 Stock
  4. Financials Celltrion, Inc.